RESULT_COUNT: 253,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
SAGE,SAGE:US,BBG0025X16Y5,Edited Transcript of SAGE earnings conference call or presentation 3-Aug-17 8:30pm GMT,2017-10-05 04:20:43 +0000,https://finance.yahoo.com/news/edited-transcript-sage-earnings-conference-184126186.html?.tsrc=rss,Q2 2017 SAGE Therapeutics Inc Earnings Call
SAGE,SAGE:US,BBG0025X16Y5,3 Beaten-Down Biotech Stocks to Buy Right Now,2017-10-02 18:00:00 +0000,http://finance.yahoo.com/r/3244bc14-3f9f-3527-9131-4b08c8b8533b/3-beaten-down-biotech-stocks-to-buy-right-now.aspx?yptr=yahoo&.tsrc=rss,"Intercept Pharmaceuticals, Exelixis, and Sage Therapeutics got pummeled in the markets last month. Each drugmaker has a solid shot at rebounding."
SAGE,SAGE:US,BBG0025X16Y5,"Noteworthy Tuesday Option Activity: SAGE, S, LAYN",2017-09-26 20:53:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9cbMbuEqqi4/noteworthy-tuesday-option-activity-sage-s-layn-cm851355,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Sage Therapeutics Inc Symbol SAGE where a total volume of 4 758 contracts has been traded thus far today a contract volume which is representative of approximately 475
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics to Participate in Leerink Investor Conference,2017-09-22 20:05:00 +0000,https://finance.yahoo.com/news/sage-therapeutics-participate-leerink-investor-200500245.html?.tsrc=rss,"Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will participate in the Leerink Partners Rare Disease Roundtable on Wednesday, September 27, 2017, with a presentation at 2:00 p.m."
SAGE,SAGE:US,BBG0025X16Y5,"Implied Volatility Surging for Sage Therapeutics, Inc. (SAGE) Stock Options",2017-09-22 14:40:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MJ-q1vAE-ps/implied-volatility-surging-for-sage-therapeutics-inc-sage-stock-options-cm849544,Investors in Sage Therapeutics Inc SAGE need to pay close attention to the stock based on moves in the options market lately That is because the Dec 15 th 2017 75 00 Call had some of the highest implied volatility of all equity options today What is Implied Volatility
SAGE,SAGE:US,BBG0025X16Y5,"Implied Volatility Surging for Sage Therapeutics, Inc. (SAGE) Stock Options",2017-09-22 12:30:12 +0000,https://finance.yahoo.com/news/implied-volatility-surging-sage-therapeutics-123012598.html?.tsrc=rss,"Surging implied volatility makes Sage Therapeutics, Inc. (SAGE) stock lucrative to the option traders."
SAGE,SAGE:US,BBG0025X16Y5,What Analysts Recommend for Sage Therapeutics,2017-09-15 19:39:09 +0000,http://finance.yahoo.com/r/24b11fbf-ba24-3cfd-97f2-5d6713440636/what-analysts-recommend-for-sage-therapeutics?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Sage Therapeutics (SAGE) is a clinical-research-based biopharmaceutical company focused on developing drugs for life-threatening central nervous system disorders.
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Could Still Become A Leader In Neurology,2017-09-15 18:06:08 +0000,https://finance.yahoo.com/news/sage-therapeutics-could-still-become-180608361.html?.tsrc=rss,"RBC Capital Markets said in a Thursday note it believes SAGE Therapeutics Inc (NASDAQ: SAGE ) can still emerge from near-term catalysts as a mid-cap neuro leader. Accordingly, the firm initiated coverage ..."
SAGE,SAGE:US,BBG0025X16Y5,What to Expect from Sage Therapeutics’ Brexanolone,2017-09-15 17:56:14 +0000,http://finance.yahoo.com/r/701f7542-f851-3f24-8524-df71bc0139b9/what-to-expect-from-sage-therapeutics-brexanolone?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Sage Therapeutics' (SAGE) Brexanolone, also known as SAGE-527, is an allosteric modulator injection under investigation."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Breaks Below 200-Day Moving Average - Notable for SAGE,2017-09-14 17:37:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TrxjEPQMsQE/sage-therapeutics-breaks-below-200-day-moving-average-notable-for-sage-cm845845,In trading on Thursday shares of Sage Therapeutics Inc Symbol SAGE crossed below their 200 day moving average of 67 82 changing hands as low as 65 01 per share Sage Therapeutics Inc shares are currently trading down about 7 1 on the day The chart below shows the one year performance of
SAGE,SAGE:US,BBG0025X16Y5,RSI Alert: Sage Therapeutics (SAGE) Now Oversold,2017-09-14 17:36:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qy3fvuri8yc/rsi-alert-sage-therapeutics-sage-now-oversold-cm845837,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
SAGE,SAGE:US,BBG0025X16Y5,"Notable Thursday Option Activity: HLF, HES, SAGE",2017-09-14 16:41:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-hkA2m4A6Uw/notable-thursday-option-activity-hlf-hes-sage-cm845779,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Herbalife Ltd Symbol HLF where a total volume of 13 595 contracts has been traded thus far today a contract volume which is representative of approximately 1 4
SAGE,SAGE:US,BBG0025X16Y5,Corporate News Blog - Sage Therapeutics Announces Top-Line Results from Phase-3 STATUS Trial of Brexanolone,2017-09-14 11:50:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-sage-therapeutics-115000311.html?.tsrc=rss,"Research Desk Line-up: Cellect Biotech Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 14, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ..."
SAGE,SAGE:US,BBG0025X16Y5,"TTOO Catches Investors' Eyes, SIEN Shaping Up, AGTC Slips Into Red",2017-09-13 22:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uBXaniUPgaE/ttoo-catches-investors-eyes-sien-shaping-up-agtc-slips-into-red-20170913-01349,"TTOO Catches Investors' Eyes, SIEN Shaping Up, AGTC Slips Into Red"
SAGE,SAGE:US,BBG0025X16Y5,The Biggest Drop in More Than a Year,2017-09-13 15:34:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/V290ZLIQqeQ/the-biggest-drop-in-more-than-a-year-cm845125,In Tuesday trading McDonald s Corp MCD shares traded lower by more than 3 after data from research firm M Science that concluded that sales projections are below Wall Street s estimates In Tuesday trading McDonald s Corp McDonald s Corp MCD shares traded lower by more than 3
SAGE,SAGE:US,BBG0025X16Y5,"Sage Therapeutics drug for rare condition deemed a failure, but company may see a path forward",2017-09-13 12:42:54 +0000,http://finance.yahoo.com/r/99063059-f3f5-381b-91b2-07d1994ef1d7/Story.aspx?guid=EBF19656-97C3-11E7-8322-8D161F05D678&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Causes of the condition could affect how well the treatment works, the company’s CEO tells MarketWatch."
SAGE,SAGE:US,BBG0025X16Y5,Down 13.69%: Is Sage Therapeutics Stock a Bad-News Buy?,2017-09-12 23:34:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nPwr3lsCbPI/down-1369-is-sage-therapeutics-stock-a-bad-news-buy-cm844648,What happened Shares of Sage Therapeutics NASDAQ SAGE a clinical stage biotech dropped by 13 69 today after the company reported that its experimental treatment for super refractory status epilepticus SRSE missed its primary endpoint in a late stage study Super
SAGE,SAGE:US,BBG0025X16Y5,"TTOO Rallies For 2nd Day, SAGE's STATUS Flops, ICPT Warns Of Ocaliva Overdosing",2017-09-12 22:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pi5wVQ83z0Y/ttoo-rallies-for-2nd-day-sages-status-flops-icpt-warns-of-ocaliva-overdosing-20170912-01561,"TTOO Rallies For 2nd Day, SAGE's STATUS Flops, ICPT Warns Of Ocaliva Overdosing"
SAGE,SAGE:US,BBG0025X16Y5,Down 13.69%: Is Sage Therapeutics Stock a Bad-News Buy?,2017-09-12 22:30:00 +0000,http://finance.yahoo.com/r/139b082c-daff-3f27-905f-ef51b028717f/down-1369-is-sage-therapeutics-stock-a-bad-news-bu.aspx?yptr=yahoo&.tsrc=rss,Sage&apos;s lead drug candidate whiffs in a late-stage study.
SAGE,SAGE:US,BBG0025X16Y5,"Alexion Could Target Sage, Ra Pharma: Analyst",2017-09-12 20:56:00 +0000,http://finance.yahoo.com/r/76c874bf-c213-3e63-ade1-76aade89a5e9/alexion-could-target-sage-ra-pharma-analyst.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,BMO Capital Markets analyst M. Ian Somaiya says Alexion could view Sage Therapeutics and Ra Pharmaceuticals as potential acquisition targets. Somaiya pointed to Sage's diverse pipeline and Ra's diversified ...
SAGE,SAGE:US,BBG0025X16Y5,"Health Care Sector Update for 09/12/2017: AEMD,ALDX,SAGE",2017-09-12 20:35:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HZDkIJ_sIYI/health-care-sector-update-for-09122017-aemdaldxsage-cm844590,Top Health Care StocksTop Health Care Stocks JNJ 0 50 JNJ 0 50 PFE 3 21 PFE 3 21 ABT 0 40 ABT 0 40 MRK 0 50 MRK 0 50 AMGN 2 27 AMGN 2 27 Health care stocks have turned narrowly higher just before Tuesday s closing bell with the NYSE Health Care Index rising nearly 0 2 today
SAGE,SAGE:US,BBG0025X16Y5,"Sage Dives On Seizure Trial, But Could Double On Depression Drugs",2017-09-12 20:10:42 +0000,http://finance.yahoo.com/r/331c118e-ed5f-3af3-98ed-1ec77243ecb9/sage-dives-on-seizure-trial-but-could-double-on-depression-drugs?src=A00220&yptr=yahoo&.tsrc=rss,Sage plummeted to a three-month low after its seizure drug failed a trial — prompting the shelving of the program.
SAGE,SAGE:US,BBG0025X16Y5,The Biggest Drop in More Than a Year,2017-09-12 19:36:47 +0000,https://finance.yahoo.com/news/biggest-drop-more-193647824.html?.tsrc=rss,3 stocks down on Tuesday
SAGE,SAGE:US,BBG0025X16Y5,Biotech: When Good Drugs Go Bad,2017-09-12 18:49:00 +0000,http://finance.yahoo.com/r/caf01149-e14c-3251-893d-0f98d8fc49cc/biotech-when-good-drugs-go-bad-1505242196?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Biotechnology is a tough business, even when things go well, as every victory is just waiting for the next piece of data to turn it into defeat. Just ask Regeneron Pharmaceuticals (REGN), which was recently ..."
SAGE,SAGE:US,BBG0025X16Y5,Sage Shows Why There Are Rules for Drug Development,2017-09-12 18:00:10 +0000,http://finance.yahoo.com/r/5da47a1f-f3da-3c5b-a558-7fcab7794d58/sage-therapeutics-brexanolone-study-moved-too-fast?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Rushing a study made Wall Street cheer, but now it's paying a price."
SAGE,SAGE:US,BBG0025X16Y5,"Health Care Sector Update for 09/12/2017: HIIQ,ALDX,SAGE",2017-09-12 17:36:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4kUlqpGr0Oc/health-care-sector-update-for-09122017-hiiqaldxsage-cm844489,Top Health Care StocksTop Health Care Stocks JNJ 0 85 JNJ 0 85 PFE 2 74 PFE 2 74 ABT 0 92 ABT 0 92 MRK 0 41 MRK 0 41 AMGN 0 86 AMGN 0 86 Health care stocks were narrowly mixed with the NYSE Health Care Index rising over 0 1 Tuesday while shares of health care companies in
SAGE,SAGE:US,BBG0025X16Y5,Is Sage Therapeutics Inc (SAGE) Undervalued?,2017-09-12 15:19:17 +0000,https://finance.yahoo.com/news/sage-therapeutics-inc-sage-undervalued-151917685.html?.tsrc=rss,"Sage Therapeutics Inc (NASDAQ:SAGE), a pharmaceuticals, biotechnology and life sciences company based in United States, See our latest analysis for SAGE Is SAGE still cheap? My valuation model shows thatRead More..."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Gets a Dunce Hat,2017-09-12 14:20:09 +0000,https://finance.yahoo.com/news/sage-therapeutics-gets-dunce-hat-142009382.html?.tsrc=rss,Sage Therapeutics saw its shares drop by about a quarter early on Tuesday after the firm gave an update on its late-stage study trial in the treatment super-refractory status epilepticus.
SAGE,SAGE:US,BBG0025X16Y5,​Trial fail for Cambridge-based Sage casts doubt on lead drug,2017-09-12 14:08:56 +0000,http://finance.yahoo.com/r/ef9f6d4d-831a-312a-a2d9-32a06c1747fb/trial-fail-for-cambridge-based-sage-casts-doubt.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Sage Therapeutics reported Tuesday morning that its drug to treat a severe and life-threatening form of epilepsy failed to meet the main goal of a late-stage trial.  As of 10 a.m. Tuesday, Sage's shares were down 17 percent to $73.62, shaving about $500 million off the company's market capitalization from yesterday's close.  There are no FDA-approved treatments for SRSE, Sage said."
SAGE,SAGE:US,BBG0025X16Y5,US STOCKS-S&P opens at record high as Irma weakens; Apple in focus,2017-09-12 13:52:27 +0000,https://finance.yahoo.com/news/us-stocks-p-opens-record-135227743.html?.tsrc=rss,"The S&P opened at a record high on  Tuesday as Irma further weakened to a post-tropical cyclone, and  ahead of the highly anticipated launch of the new iPhone.  The weakening of Irma, the second major natural disaster to  hit the United States after Hurricane Harvey, allayed concerns  about the severity of its financial impact.  ""Investors have gained confidence that the worst is over and  concerns over Irma's economic impact seem to have disappeared  for the moment,"" said Andre Bakhos, managing director of Janlyn  Capital in Bernardsville, New Jersey."
SAGE,SAGE:US,BBG0025X16Y5,US STOCKS-Wall St set to open higher as Irma weakens; Apple in focus,2017-09-12 12:58:48 +0000,https://finance.yahoo.com/news/us-stocks-wall-st-set-125848938.html?.tsrc=rss,"Wall Street was set to open higher on  Tuesday as Irma further weakened to a post-tropical cyclone, and  ahead of the highly anticipated launch of the new iPhone.  The weakening of Irma, the second major natural disaster to  hit the United States after Hurricane Harvey, allayed concerns  about the severity of its financial impact.  ""Investors have gained confidence that the worst is over and  concerns over Irma's economic impact seem to have disappeared  for the moment,"" said Andre Bakhos, managing director of Janlyn  Capital in Bernardsville, New Jersey."
SAGE,SAGE:US,BBG0025X16Y5,"Pre-Market Most Active for Sep 12, 2017 :  TEVA, AEG, SAGE, AAPL, TVIX, MT, NOK, AZN, CS, MRNS, ICPT, KWEB",2017-09-12 12:54:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gSYdKhZjtfw/pre-market-most-active-for-sep-12-2017-teva-aeg-sage-aapl-tvix-mt-nok-azn-cs-mrns-icpt-kweb-cm844183,The NASDAQ 100 Pre Market Indicator is up 18 28 to 5 998 81 The total Pre Market volume is currently 6 935 694 shares traded The following are the most active stocks for the pre market session Teva Pharmaceutical Industries Limited TEVA is 1 37 at 19 87 with 3 155
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics' stock sinks after disappointing late-stage trial of SRSE treatment,2017-09-12 11:57:09 +0000,http://finance.yahoo.com/r/4e4b1d94-585e-304c-a229-6798bc383871/Story.aspx?guid=ADEA6F3E-B699-42C2-B32E-C7FB43DCAD4D&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Shares of Sage Therapeutics Inc. sank 24% in active premarket trade Tuesday, pulling back from the previous session's record close, after the biopharmaceutical company said its treatment of super-refractory ..."
SAGE,SAGE:US,BBG0025X16Y5,Sage's seizure disorder drug fails late-stage trial,2017-09-12 10:16:41 +0000,https://finance.yahoo.com/news/sages-seizure-disorder-drug-fails-101641851.html?.tsrc=rss,"Sage Therapeutics Inc said on Tuesday its drug to treat a life-threatening seizure disorder failed to meet the main goal of a late-stage trial. The trial was testing Sage's drug, brexanolone, plus standard ..."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Reports Top-Line Results from Phase 3 STATUS Trial of Brexanolone in Super-Refractory Status Epilepticus,2017-09-12 10:00:00 +0000,https://finance.yahoo.com/news/sage-therapeutics-reports-top-line-100000557.html?.tsrc=rss,"Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today reported top-line results from its Phase 3 STATUS Trial of brexanolone in the treatment super-refractory status epilepticus ."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics (SAGE) Has Dropped To A 3-Month Low After Study Failed,2017-09-12 09:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TjVxEJ5uVrc/sage-therapeutics-sage-has-dropped-to-a-3month-low-after-study-failed-20170912-00846,Sage Therapeutics (SAGE) Has Dropped To A 3-Month Low After Study Failed
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics: Brexanolone STATUS Trial Fails To Achieve Primary Endpoint,2017-09-12 06:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ioZN6qwGa-4/sage-therapeutics-brexanolone-status-trial-fails-to-achieve-primary-endpoint-20170912-00253,Sage Therapeutics: Brexanolone STATUS Trial Fails To Achieve Primary Endpoint
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics to Present at Morgan Stanley Healthcare Conference,2017-09-07 20:05:00 +0000,https://finance.yahoo.com/news/sage-therapeutics-present-morgan-stanley-200500750.html?.tsrc=rss,"Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 13, 2017 at 8:45 a.m."
SAGE,SAGE:US,BBG0025X16Y5,Brexanolone Could Strengthen Ligand’s Neurology Portfolio,2017-09-06 20:05:48 +0000,http://finance.yahoo.com/r/ade79c56-a851-3e24-b321-6a8805521087/brexanolone-expected-strengthen-ligand-pharmaceuticals-neurology-portfolio?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Sage Therapeutics is also exploring Brexanolone in moderate and severe post-partum depression (or PPD) patients in two separate Phase 3 trials.
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),2017-09-06 20:05:00 +0000,https://finance.yahoo.com/news/sage-therapeutics-announces-inducement-grants-200500519.html?.tsrc=rss,"Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, announced that, on September 1, 2017, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 52,800 shares of its common stock to four new employees under Sage’s 2016 Inducement Equity Plan...."
SAGE,SAGE:US,BBG0025X16Y5,Look Under The Hood: VTWG Has 11% Upside,2017-08-31 14:49:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kDMsmpSFUcI/look-under-the-hood-vtwg-has-11-upside-cm839621,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
SAGE,SAGE:US,BBG0025X16Y5,Options Traders Expect Huge Moves in Sage Therapeutics (SAGE) Stock,2017-08-28 14:54:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v2V6QwICR20/options-traders-expect-huge-moves-in-sage-therapeutics-sage-stock-cm837904,Investors in Sage Therapeutics Inc SAGE need to pay close attention to the stock based on moves in the options market lately That is because the Sep 15 th 2017 70 00 160 Put had some of the highest implied volatility of all equity options today What is Implied Volatility
SAGE,SAGE:US,BBG0025X16Y5,Options Traders Expect Huge Moves in Sage Therapeutics (SAGE) Stock,2017-08-28 12:41:12 +0000,https://finance.yahoo.com/news/options-traders-expect-huge-moves-124112828.html?.tsrc=rss,Options Traders Expect Huge Moves in Sage Therapeutics (SAGE) Stock on the back of its high level of implied volatility.
SAGE,SAGE:US,BBG0025X16Y5,SAGE October 20th Options Begin Trading,2017-08-07 16:36:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/u9fvBJfsCgY/sage-october-20th-options-begin-trading-cm828135,Investors in Sage Therapeutics Inc Symbol SAGE saw new options begin trading today for the October 20th expiration One of the key inputs that goes into the price an option buyer is willing to pay is the time value so with 74 days until expiration the newly trading contracts represent
SAGE,SAGE:US,BBG0025X16Y5,Today's Research Reports on Stocks to Watch: Neurocrine Biosciences and Sage Therapeutics,2017-08-07 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-120000505.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 7, 2017 / Despite a wider net loss in the second quarter than compared to a year ago, shares of Neurocrine still closed up nearly 10% on Friday after reporting impressive ..."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces Second Quarter 2017 Financial Results and Provides Pipeline Update,2017-08-03 20:01:00 +0000,https://finance.yahoo.com/news/sage-therapeutics-announces-second-quarter-200100289.html?.tsrc=rss,"Sage Therapeutics, Inc.  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today reported business highlights and financial results for the second quarter ended June 30, 2017."
SAGE,SAGE:US,BBG0025X16Y5,"Investor Network: SAGE Therapeutics, Inc. to Host Earnings Call",2017-08-03 16:10:00 +0000,https://finance.yahoo.com/news/investor-network-sage-therapeutics-inc-161000656.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 3, 2017 / SAGE Therapeutics, Inc. (NASDAQ: SAGE ) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, August 3, 2017 at 4:30 PM ..."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Reaches Analyst Target Price,2017-07-25 13:58:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D3vGo825Lgo/sage-therapeutics-reaches-analyst-target-price-cm820759,In recent trading shares of Sage Therapeutics Inc Symbol SAGE have crossed above the average analyst 12 month target price of 85 00 changing hands for 85 89 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
SAGE,SAGE:US,BBG0025X16Y5,"Sage Therapeutics to Report Second Quarter 2017 Financial Results on Thursday, August 3, 2017",2017-07-20 20:10:00 +0000,https://finance.yahoo.com/news/sage-therapeutics-report-second-quarter-201000513.html?.tsrc=rss,"Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 3, 2017 at 4:30 pm ET to report its second quarter 2017 financial results and to discuss recent business updates."
SAGE,SAGE:US,BBG0025X16Y5,"Noteworthy Monday Option Activity: LSI, CSX, SAGE",2017-07-10 20:45:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pSmWIxZJBG4/noteworthy-monday-option-activity-lsi-csx-sage-cm814054,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Life Storage Inc Symbol LSI where a total volume of 1 825 contracts has been traded thus far today a contract volume which is representative of approximately 182
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),2017-07-10 20:10:00 +0000,https://finance.yahoo.com/news/sage-therapeutics-announces-inducement-grants-201000834.html?.tsrc=rss,"Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, announced that, on July 3, 2017, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 9,000 shares of its common stock to one new employee under Sage’s 2016 Inducement Equity Plan."
SAGE,SAGE:US,BBG0025X16Y5,UNC working with Mass. pharma company on depression drug,2017-06-14 14:35:09 +0000,http://finance.yahoo.com/r/b9ba8311-09b6-3cdf-b2d9-ea7c33beed64/unc-working-with-mass-pharma-company-on-depression.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Researchers at the University of North Carolina School of Medicine are working with Cambridge, Massachusetts-based biopharmaceutical company Sage Therapeutics (SAGE) on clinical trials of a drug for the treatment of severe postpartum depression (PPD).  A multi-site Phase 3 trial for the drug called brexanolone is currently underway at the Perinatal Psychiatry Program at the UNC School of Medicine and promising results of a Phase 2 trial were published this week in The Lancet medical journal.  “We know that one in eight women that give birth will have symptoms of PPD or anxiety…” says Dr. Samantha Meltzer-Brody, director of the Perinatal Psychiatry Program, academic principal investigator and senior author of the study published in The Lancet."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces The Lancet Publishes Positive Phase 2 Brexanolone (SAGE-547) Clinical Data in Severe Postpartum Depression,2017-06-12 22:41:00 +0000,https://finance.yahoo.com/news/sage-therapeutics-announces-lancet-publishes-224100069.html?.tsrc=rss,"Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that The Lancet has published results from a Phase 2, double-blind, randomized and placebo-controlled study of brexanolone in women with severe postpartum depression ."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics to Present at Goldman Sachs Healthcare Conference,2017-06-08 20:01:00 +0000,https://finance.yahoo.com/news/sage-therapeutics-present-goldman-sachs-200100763.html?.tsrc=rss,"Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will present at the Goldman Sachs Global Healthcare Conference on Wednesday, June 14, 2017 at 4:20 p.m."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),2017-06-05 11:00:00 +0000,https://finance.yahoo.com/news/sage-therapeutics-announces-inducement-grants-110000904.html?.tsrc=rss,"Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, announced that, on June 1, 2017, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 36,000 shares of its common stock to two new employees under Sage’s 2016 Inducement Equity Plan."
SAGE,SAGE:US,BBG0025X16Y5,Biotech Movers: Fast Track Designation Sends Sage Shares Higher,2017-05-18 13:57:00 +0000,http://finance.yahoo.com/r/f865659b-e02c-3f61-838c-1aaecd8f71e9/biotech-movers-fast-track-designation-sends-sage-shares-higher.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Sage Therapeutics, Incyte and Shire were among the biotech movers in premarket trading on Thursday."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Receives Fast Track Designation for SAGE-217 for the Treatment of Major Depressive Disorder,2017-05-18 11:00:00 +0000,https://finance.yahoo.com/news/sage-therapeutics-receives-fast-track-110000509.html?.tsrc=rss,"Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the U.S."
SAGE,SAGE:US,BBG0025X16Y5,"ARRY Hits Trial Goals, DEPO Falls On Q1 Results, SAGE Awaits Data In Q3",2017-05-10 01:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Zfgxi_f0tJk/arry-hits-trial-goals-depo-falls-on-q1-results-sage-awaits-data-in-q3-20170510-00077,"ARRY Hits Trial Goals, DEPO Falls On Q1 Results, SAGE Awaits Data In Q3"
SAGE,SAGE:US,BBG0025X16Y5,"Noteworthy Tuesday Option Activity: JCOM, SAGE, PEGA",2017-05-09 21:02:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VZJCftmVAWs/noteworthy-tuesday-option-activity-jcom-sage-pega-cm786819,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in j2 Global Inc Symbol JCOM where a total volume of 5 758 contracts has been traded thus far today a contract volume which is representative of approximately 575 800
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics reports 1Q loss,2017-05-09 20:06:51 +0000,http://finance.yahoo.com/news/sage-therapeutics-reports-1q-loss-200651565.html?.tsrc=rss,"The Cambridge, Massachusetts-based company said it had a loss of $1.52 per share. The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research ..."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces First Quarter 2017 Financial Results and Provides Pipeline Update,2017-05-09 20:01:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-announces-first-quarter-200100456.html?.tsrc=rss,"Sage Therapeutics, Inc.  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today reported business highlights and financial results for the first quarter ended March 31, 2017."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),2017-05-04 20:01:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-announces-inducement-grants-200100193.html?.tsrc=rss,"Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, announced that, on May 1, 2017, the Compensation Committee of Sage’s Board of Directors granted a non-qualified stock option for the purchase of 185,000 shares to Michael Cloonan in connection with his joining Sage as Chief Business Officer, and granted ..."
SAGE,SAGE:US,BBG0025X16Y5,Implied FTXH Analyst Target Price: $24,2017-05-03 13:27:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H8ztPYeqQIE/implied-ftxh-analyst-target-price-24-cm783384,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces Initiation of Phase 1 Development and First Dosing of SAGE-718,2017-04-27 11:00:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-announces-initiation-phase-110000731.html?.tsrc=rss,"Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced it has initiated a Phase 1 single ascending dose trial of SAGE-718 in healthy volunteers."
SAGE,SAGE:US,BBG0025X16Y5,"Notable Wednesday Option Activity: CHRW, ACXM, SAGE",2017-04-26 20:44:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Etx0kulDEEY/notable-wednesday-option-activity-chrw-acxm-sage-cm779841,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in C H Robinson Worldwide Inc Symbol CHRW where a total volume of 5 725 contracts has been traded thus far today a contract volume which is representative of
SAGE,SAGE:US,BBG0025X16Y5,"Cramer's lightning round: Buy, buy, buy this high-flying bank stock",2017-04-25 22:49:24 +0000,http://finance.yahoo.com/r/4dfbcded-49ad-3fb9-8845-7d8e8e15e4bc/104425277?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104425277&yptr=yahoo&.tsrc=rss,"Jim Cramer sped through his take on caller favorite stocks, including this outperforming bank."
SAGE,SAGE:US,BBG0025X16Y5,"Cramer&apos;s lightning round: Buy, buy, buy this high-flying bank stock",2017-04-25 22:49:24 +0000,http://finance.yahoo.com/news/cramer-apos-lightning-round-buy-224924636.html?.tsrc=rss,"Jim Cramer sped through his take on caller favorite stocks, including this outperforming bank."
SAGE,SAGE:US,BBG0025X16Y5,"Sage Therapeutics to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017",2017-04-25 20:01:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-report-first-quarter-200100142.html?.tsrc=rss,"Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, May 9, 2017 at 4:30 pm ET to report its first quarter 2017 financial results and to discuss recent business updates."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Appoints Michael Cloonan as Chief Business Officer and Expands Executive Team,2017-04-24 11:00:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-appoints-michael-cloonan-110000405.html?.tsrc=rss,"Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced the appointment of Michael Cloonan as Chief Business Officer."
SAGE,SAGE:US,BBG0025X16Y5,"Wednesday's ETF Movers: XBI, GDXJ",2017-04-19 18:03:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_87vpZF7VaQ/wednesdays-etf-movers-xbi-gdxj-cm775972,In trading on Wednesday the SPDR S amp P Biotech ETF is outperforming other ETFs up about 1 5 on the day Components of that ETF showing particular strength include shares of Insmed up about 5 7 and shares of Sage Therapeutics up about 5 on the day And underperforming other ETFs
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics to Present at American Academy of Neurology 2017 Annual Meeting,2017-04-19 11:00:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-present-american-academy-110000155.html?.tsrc=rss,"Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced upcoming presentations for brexanolone and SAGE-217 at the American Academy of Neurology 2017 Annual Meeting, taking place April 22-28, 2017 in Boston, Mass."
SAGE,SAGE:US,BBG0025X16Y5,"Noteworthy Monday Option Activity: SAGE, THO, ATH",2017-04-17 20:54:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8XL1zRxM-BQ/noteworthy-monday-option-activity-sage-tho-ath-cm774839,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Sage Therapeutics Inc Symbol SAGE where a total of 15 340 contracts have traded so far representing approximately 1 5 million underlying shares That amounts to about 354 5 of SAGE
SAGE,SAGE:US,BBG0025X16Y5,Trader makes bullish bet on Sage Therapeutics,2017-04-17 18:34:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XLXJTMAWf6s/trader-makes-bullish-bet-on-sage-therapeutics-cm774799,Option traders are making a bet on a rise in shares of Sage Therapeutics SAGE Monday A single lot of 2 472 contracts of the June 100 call crossed the tape at a little after noon ET today Previous open interest at the strike was zero and these contracts moved on the high side of a
SAGE,SAGE:US,BBG0025X16Y5,Cramer's charts show these biotechs ignoring their 'polit...,2017-04-11 22:53:00 +0000,http://finance.yahoo.com/video/cramers-charts-show-biotechs-ignoring-225300315.html?.tsrc=rss,Jim Cramer looks to Bob Lang's charts to reveal major biotech names that are rallying despite Washington's drug pricing controversy.
SAGE,SAGE:US,BBG0025X16Y5,Cramer's charts show these biotechs ignoring their 'political red herring',2017-04-11 22:22:40 +0000,http://finance.yahoo.com/r/faf01864-d867-3fe0-b4cb-0b029e7ca50a/104398059?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104398059&yptr=yahoo&.tsrc=rss,Jim Cramer looks to Bob Lang's charts to reveal major biotech names that are rallying despite Washington's drug pricing controversy.
SAGE,SAGE:US,BBG0025X16Y5,Cramer&apos;s charts show these biotechs ignoring their &apos;political red herring&apos;,2017-04-11 22:22:40 +0000,http://finance.yahoo.com/news/cramers-charts-show-biotechs-ignoring-222240369.html?.tsrc=rss,Jim Cramer looks to Bob Lang&apos;s charts to reveal major biotech names that are rallying despite Washington&apos;s drug pricing controversy.
SAGE,SAGE:US,BBG0025X16Y5,"Noteworthy Friday Option Activity: PTLA, CSV, SAGE",2017-04-07 20:53:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ekuGzhHpiss/noteworthy-friday-option-activity-ptla-csv-sage-cm771586,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Portola Pharmaceuticals Inc Symbol PTLA where a total volume of 6 308 contracts has been traded thus far today a contract volume which is representative of
SAGE,SAGE:US,BBG0025X16Y5,5 Drug Stocks for Your Portfolio this World Health Day,2017-04-07 14:58:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CYrtPf03ucM/5-drug-stocks-for-your-portfolio-this-world-health-day-cm771289,World Health Day is celebrated on Apr 7 every year to mark the anniversary of the founding of the World Health Organization WHO Every year the focus is on a specific health topic of concern with the goal being to raise awareness and address the issue This World Health Day the focus is
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),2017-04-05 20:01:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-announces-inducement-grants-200100057.html?.tsrc=rss,"Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, announced that, on April 3, 2017, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 295,000 shares of its common stock to 15 new employees under Sage’s 2016 Inducement Equity Plan."
SAGE,SAGE:US,BBG0025X16Y5,Pershing Gold to Present at 2017 European Gold Forum,2017-04-03 12:00:00 +0000,http://finance.yahoo.com/news/pershing-gold-present-2017-european-120000943.html?.tsrc=rss,"LAKEWOOD, Colo., April 3, 2017 /PRNewswire/ -- Pershing Gold Corporation (NASDAQ:PGLC) (TSX: PGLC) (FWB:7PG1) (""Pershing Gold"" or the ""Company""), the emerging Nevada gold producer advancing ..."
SAGE,SAGE:US,BBG0025X16Y5,Pershing Gold to Present at 2017 European Gold Forum,2017-04-03 12:00:00 +0000,http://finance.yahoo.com/news/pershing-gold-present-2017-european-120000877.html,[CNW Group] - Pershing Gold to Present at 2017 European Gold Forum
SAGE,SAGE:US,BBG0025X16Y5,Pershing Gold to Present at 2017 European Gold Forum,2017-04-03 12:00:00 +0000,http://finance.yahoo.com/news/pershing-gold-present-2017-european-120000877.html?.tsrc=rss,Pershing Gold to Present at 2017 European Gold Forum
SAGE,SAGE:US,BBG0025X16Y5,"Biotech Premarket Movers: Sage Therapeutics, Depomed, NantKwest",2017-03-31 13:28:00 +0000,http://finance.yahoo.com/r/0486cccd-f876-3e56-9bb7-3b4941f184fe/biotech-premarket-movers-sage-therapeutics-depomed-nantkwest.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Sage Therapeutics, Depomed and NantKwest were among the biotech stock movers in premarket trading on Friday."
SAGE,SAGE:US,BBG0025X16Y5,"Biotech Premarket Movers: Sage Therapeutics, Depomed, NantKwest",2017-03-31 13:28:00 +0000,https://www.thestreet.com/story/14067582/1/biotech-premarket-movers-sage-therapeutics-depomed-nantkwest.html?puc=yahoo&cm_ven=YAHOO,"Biotech Premarket Movers: Sage Therapeutics, Depomed, NantKwest"
SAGE,SAGE:US,BBG0025X16Y5,Are Options Traders Betting on a Big Move in Sage Therapeutics (SAGE) Stock?,2017-03-30 15:04:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/229WEaqFaSI/are-options-traders-betting-on-a-big-move-in-sage-therapeutics-sage-stock-cm767689,Investors in Sage Therapeutics Inc SAGE need to pay close attention to the stock based on moves in the options market lately That is because the Jun 16 th 45 00 Put had some of the highest implied volatility of all equity options today What is Implied Volatility Implied
SAGE,SAGE:US,BBG0025X16Y5,Are Options Traders Betting on a Big Move in Sage Therapeutics (SAGE) Stock?,2017-03-30 12:47:12 +0000,http://finance.yahoo.com/news/options-traders-betting-big-move-124712815.html,Are Options Traders Betting on a Big Move in Sage Therapeutics (SAGE) Stock?
SAGE,SAGE:US,BBG0025X16Y5,Are Options Traders Betting on a Big Move in Sage Therapeutics (SAGE) Stock?,2017-03-30 12:47:12 +0000,http://finance.yahoo.com/news/options-traders-betting-big-move-124712815.html?.tsrc=rss,Options Traders are Betting on a Big Move in Sage Therapeutics (SAGE) Stock on the back of its huge implied volatility.
SAGE,SAGE:US,BBG0025X16Y5,"Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk",2017-03-24 12:34:00 +0000,http://finance.yahoo.com/r/e6155a1d-8b33-3904-8072-3b874acf9388/biotech-stock-mailbag-sage-therapeutics-cellceutix-alzheimer-s-risk.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
SAGE,SAGE:US,BBG0025X16Y5,"Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk",2017-03-24 12:34:00 +0000,https://www.thestreet.com/story/14058387/1/biotech-stock-mailbag-sage-therapeutics-cellceutix-alzheimer-s-risk.html?puc=yahoo&cm_ven=YAHOO,"Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk"
SAGE,SAGE:US,BBG0025X16Y5,"Notable Friday Option Activity: MSFT, NLNK, SAGE",2017-03-17 21:06:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n-Feqlxd7fU/notable-friday-option-activity-msft-nlnk-sage-cm762428,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Microsoft Corporation Symbol MSFT where a total of 106 072 contracts have traded so far representing approximately 10 6 million underlying shares That amounts to about 51 7
SAGE,SAGE:US,BBG0025X16Y5,"SAGE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers",2017-03-09 21:24:19 +0000,http://biz.yahoo.com/e/170309/sage8-k.html,"SAGE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers"
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),2017-03-02 21:20:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-announces-inducement-grants-212000702.html,"[Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, announced that, on March 1, 2017, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 67,000 shares of its common stock to four new employees under Sage’s 2016 Inducement Equity Plan."
SAGE,SAGE:US,BBG0025X16Y5,"SAGE THERAPEUTICS, INC. Financials",2017-03-02 18:04:18 +0000,http://finance.yahoo.com/q/is?s=sage,"SAGE THERAPEUTICS, INC. Financials"
SAGE,SAGE:US,BBG0025X16Y5,Blog Coverage La Jolla's Lead Product Candidate LJPC-501 Posts Positive Phase-III Trial Results,2017-02-28 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-la-jollas-lead-131500692.html,"[Accesswire] - Upcoming AWS Coverage on Sage Therapeutics Post-Earnings Results LONDON, UK / ACCESSWIRE / February 28, 2017 / Active Wall St. blog coverage looks at the headline from La Jolla Pharmaceutical Co. (NASDAQ: ..."
SAGE,SAGE:US,BBG0025X16Y5,Blog Coverage La Jolla's Lead Product Candidate LJPC-501 Posts Positive Phase-III Trial Results,2017-02-28 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-la-jollas-lead-131500692.html?.tsrc=rss,"Upcoming AWS Coverage on Sage Therapeutics Post-Earnings Results LONDON, UK / ACCESSWIRE / February 28, 2017 / Active Wall St. blog coverage looks at the headline from La Jolla Pharmaceutical Co. (NASDAQ: ..."
SAGE,SAGE:US,BBG0025X16Y5,"SAGE THERAPEUTICS, INC. Files SEC form 10-K, Annual Report",2017-02-24 22:10:46 +0000,http://biz.yahoo.com/e/170224/sage10-k.html,"SAGE THERAPEUTICS, INC. Files SEC form 10-K, Annual Report"
SAGE,SAGE:US,BBG0025X16Y5,"SAGE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E",2017-02-23 21:55:54 +0000,http://biz.yahoo.com/e/170223/sage8-k.html,"SAGE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E"
SAGE,SAGE:US,BBG0025X16Y5,Q4 2016 SAGE Therapeutics Inc Earnings Release - Before Market Open,2017-02-23 12:07:05 +0000,http://biz.yahoo.com/research/earncal/20170223.html?t=sage,Q4 2016 SAGE Therapeutics Inc Earnings Release - Before Market Open
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics reports 4Q loss,2017-02-23 11:42:52 +0000,http://finance.yahoo.com/news/sage-therapeutics-reports-4q-loss-114252697.html?.tsrc=rss,"On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.50. The results did not meet Wall Street expectations. The average estimate of nine analysts surveyed by Zacks ..."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics reports 4Q loss,2017-02-23 11:42:52 +0000,http://sg.finance.yahoo.com/news/sage-therapeutics-reports-4q-loss-114252376.html,Sage Therapeutics reports 4Q loss
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update,2017-02-23 11:30:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-announces-fourth-quarter-113000674.html,"[Business Wire] - Sage Therapeutics, Inc. today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2016."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update,2017-02-23 11:30:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-announces-fourth-quarter-113000674.html?.tsrc=rss,"Sage Therapeutics, Inc.  today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2016."
SAGE,SAGE:US,BBG0025X16Y5,First Week of SAGE April 21st Options Trading,2017-02-22 16:52:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rgpoTFIG-2M/first-week-of-sage-april-21st-options-trading-cm751421,Investors in Sage Therapeutics Inc Symbol SAGE saw new options become available this week for the April 21st expiration At Stock Options Channel our YieldBoost formula has looked up and down the SAGE options chain for the new April 21st contracts and identified one put and one call
SAGE,SAGE:US,BBG0025X16Y5,"Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More",2017-02-22 15:12:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KcgF6FkWn34/drug-stocks-q4-earnings-slated-for-feb-23-bmrn-icpt-more-cm751080,The fourth quarter earnings season is drawing to a close with results from 411 S amp P 500 members or 82 2 of the index s total membership already out as of Feb 22 2017 according to the latest Earnings Preview report Total earnings for these 411 index members were up 8 from the year
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Takes Investors On A Wild Ride As CEO Talks Up Brain Drugs,2017-02-22 14:10:00 +0000,http://finance.yahoo.com/r/b2726e01-4c17-3f2b-b26e-0453cec1537b/sage-therapeutics-takes-investors-on-a-wild-ride-as-ceo-talks-up-brain-drugs?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,Sage Therapeutics has been whipping its investors into a frenzy of late. But there are important milestones coming this year that the biotech will have to cross to live up to high expectations.
SAGE,SAGE:US,BBG0025X16Y5,"Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More",2017-02-22 13:29:01 +0000,http://finance.yahoo.com/news/drug-stocks-q4-earnings-slated-132901558.html,"Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More"
SAGE,SAGE:US,BBG0025X16Y5,"Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More",2017-02-22 13:29:01 +0000,http://finance.yahoo.com/news/drug-stocks-q4-earnings-slated-132901558.html?.tsrc=rss,"The fourth-quarter earnings season is drawing to a close with results from 411 S&P 500 members or 82.2% of the index's total membership already out, as of Feb 22, 2017."
SAGE,SAGE:US,BBG0025X16Y5,SAGE Therapeutics downgraded by H.C. Wainwright,2017-02-22 12:11:48 +0000,http://finance.yahoo.com/q/ud?s=SAGE,SAGE Therapeutics downgraded by H.C. Wainwright
SAGE,SAGE:US,BBG0025X16Y5,Baron Opportunity Fund Comments on Sage Therapeutics,2017-02-21 16:57:39 +0000,http://finance.yahoo.com/news/baron-opportunity-fund-comments-sage-165739159.html,Baron Opportunity Fund Comments on Sage Therapeutics
SAGE,SAGE:US,BBG0025X16Y5,Baron Opportunity Fund Comments on Sage Therapeutics,2017-02-21 16:57:39 +0000,http://finance.yahoo.com/news/baron-opportunity-fund-comments-sage-165739159.html?.tsrc=rss,Guru stock highlight
SAGE,SAGE:US,BBG0025X16Y5,Baron Opportunity Fund Shareholder 4th Quarter Commentary,2017-02-21 16:39:45 +0000,http://finance.yahoo.com/news/baron-opportunity-fund-shareholder-4th-163945931.html,Baron Opportunity Fund Shareholder 4th Quarter Commentary
SAGE,SAGE:US,BBG0025X16Y5,Baron Opportunity Fund Shareholder 4th Quarter Commentary,2017-02-21 16:39:45 +0000,http://finance.yahoo.com/news/baron-opportunity-fund-shareholder-4th-163945931.html?.tsrc=rss,Review of markets and holdings
SAGE,SAGE:US,BBG0025X16Y5,3:05 am SAGE Therapeutics issues statement that co is not in M&A discussions,2017-02-20 08:05:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#sage,3:05 am SAGE Therapeutics issues statement that co is not in M&A discussions
SAGE,SAGE:US,BBG0025X16Y5,[$$] OVERHEARD: Talking Too Much?,2017-02-18 04:33:50 +0000,https://www.wsj.com/articles/overheard-talking-too-much-1487383802?ru=yahoo?mod=yahoo_itp,[$$] OVERHEARD: Talking Too Much?
SAGE,SAGE:US,BBG0025X16Y5,[$$] OVERHEARD: Talking Too Much?,2017-02-18 04:33:50 +0000,http://finance.yahoo.com/r/9680b1cb-e372-3cbf-9a67-b2abe9dae5f4/overheard-talking-too-much-1487383802?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,"Pharmaceutical company Sage Therapeutics says its policy is to not comment on speculation about takeover activity. It should tell that to its own chief executive, who sparked talk of a buyout Thursday...."
SAGE,SAGE:US,BBG0025X16Y5,"Noteworthy Friday Option Activity: SAGE, BAX, CLVS",2017-02-17 21:51:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/i4C2RjUcrKo/noteworthy-friday-option-activity-sage-bax-clvs-cm749833,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Sage Therapeutics Inc Symbol SAGE where a total volume of 2 971 contracts has been traded thus far today a contract volume which is representative of approximately 297
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Leads Biotech Movers on False Takeout Rumors,2017-02-17 14:42:00 +0000,https://www.thestreet.com/story/14006574/1/sage-therapeutics-leads-biotech-movers-on-takeout-rumor.html?puc=yahoo&cm_ven=YAHOO,Sage Therapeutics Leads Biotech Movers on False Takeout Rumors
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Leads Biotech Movers on False Takeout Rumors,2017-02-17 14:42:00 +0000,http://finance.yahoo.com/r/975a39e9-3967-3a34-aa72-2ad6dd013450/sage-therapeutics-leads-biotech-movers-on-takeout-rumor.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"In addition to Sage Therapeutics, also moving biotech Friday: Novavax, Cytokinetics and Acadia Pharmaceuticals."
SAGE,SAGE:US,BBG0025X16Y5,"Sage Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, February 23, 2017",2017-02-17 12:00:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-report-fourth-quarter-120000379.html?.tsrc=rss,"Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, February 23, 2017 at 8:00 am ET to report its fourth quarter and full year 2016 financial results and to discuss recent business updates."
SAGE,SAGE:US,BBG0025X16Y5,"Sage Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, February 23, 2017",2017-02-17 12:00:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-report-fourth-quarter-120000379.html,"[Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, February 23, 2017 at 8:00 am ET to report its fourth quarter and full year 2016 financial results and to discuss recent business updates."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Not in M&A Discussions: STATEMENT,2017-02-17 00:45:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-not-m-discussions-004500794.html,"[Business Wire] - Sage Therapeutics - On February 16, 2017, Chief Executive Officer Jeff Jonas conducted an interview about SAGE-217 in major depressive disorder . During the course of the interview, Dr."
SAGE,SAGE:US,BBG0025X16Y5,Stress boom to boost drug sales?,2017-02-16 22:38:00 +0000,http://finance.yahoo.com/video/stress-boom-boost-drug-sales-223800695.html?.tsrc=rss,"Americans are stressed out now more than ever, and some drug companies may end up reaping the benefits. CNBC's Meg Tirrell reports. The &quot;Fast Money&quot; traders weigh in."
SAGE,SAGE:US,BBG0025X16Y5,Stress boom to boost drug sales?,2017-02-16 22:38:00 +0000,http://finance.yahoo.com/video/stress-boom-boost-drug-sales-223800695.html,Stress boom to boost drug sales?
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics shares jump after depression drug trial results,2017-02-13 23:19:19 +0000,http://www.cnbc.com/id/104279092?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104279092,Sage Therapeutics shares jump after depression drug trial results
SAGE,SAGE:US,BBG0025X16Y5,Why Sage Therapeutics Jumped Today,2017-02-13 23:18:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0VzfzZPQjb4/why-sage-therapeutics-jumped-today-cm747326,What happened After releasing encouraging data from Part A of a Phase 2 trial shares of SAGE Therapeutics NASDAQ SAGE a 160 clinical stage biotech focused on diseases of the central nervous system rose by 14 as of 3 20 p m EST on Monday So what
SAGE,SAGE:US,BBG0025X16Y5,Why Sage Therapeutics Jumped Today,2017-02-13 22:17:17 +0000,http://www.fool.com/investing/2017/02/13/why-sage-therapeutics-jumped-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Sage Therapeutics Jumped Today
SAGE,SAGE:US,BBG0025X16Y5,"Gainers & Losers Of The Day: ZSAN, PLSE, XOMA, SAGE, CBIO...",2017-02-13 21:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kp9aiqfn-V0/gainers--losers-of-the-day-zsan-plse-xoma-sage-cbio-20170213-01457,"Gainers & Losers Of The Day: ZSAN, PLSE, XOMA, SAGE, CBIO..."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Lifts Investor Spirits With Sliver of Depression Drug Data,2017-02-13 17:38:00 +0000,https://www.thestreet.com/story/14000033/1/sage-therapeutics-lifts-investor-spirits-with-tiny-sliver-of-depression-drug-data.html?puc=yahoo&cm_ven=YAHOO,Sage Therapeutics Lifts Investor Spirits With Sliver of Depression Drug Data
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Surges: A Little Bit Of Data Goes A Long Way,2017-02-13 17:27:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/02/13/sage-therapeutics-surges-a-little-bit-of-data-goes-a-long-way/?mod=yahoobarrons&ru=yahoo,Sage Therapeutics Surges: A Little Bit Of Data Goes A Long Way
SAGE,SAGE:US,BBG0025X16Y5,Can Sage Therapeutics Press Even Further With Its Depression Trial?,2017-02-13 17:10:52 +0000,http://finance.yahoo.com/news/sage-therapeutics-press-even-further-171052029.html,Can Sage Therapeutics Press Even Further With Its Depression Trial?
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics gains $220M in value as depression drug clears trial hurdle,2017-02-13 16:15:08 +0000,http://www.bizjournals.com/boston/news/2017/02/13/sage-therapeutics-gains-220m-in-value-as.html?ana=yahoo,Sage Therapeutics gains $220M in value as depression drug clears trial hurdle
SAGE,SAGE:US,BBG0025X16Y5,"Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics",2017-02-13 14:24:00 +0000,https://www.thestreet.com/story/13999596/1/biotech-premarket-movers-sage-therapeutics-immunomedics-myriad-genetics.html?puc=yahoo&cm_ven=YAHOO,"Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics"
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Advances SAGE-217 into Placebo-Controlled Phase 2 Clinical Trial in Major Depressive Disorder,2017-02-13 12:00:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-advances-sage-217-120000424.html,"[Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced encouraging top-line results from its Phase 2 clinical trial of orally-administered SAGE-217 for the treatment of major depressive disorder ."
SAGE,SAGE:US,BBG0025X16Y5,SAGE Therapeutics Inc. (SAGE) Is Climbing On Phase 2 Study Results,2017-02-13 09:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FKebEc1RRrI/sage-therapeutics-inc-sage-is-climbing-on-phase-2-study-results-20170213-00768,SAGE Therapeutics Inc. (SAGE) Is Climbing On Phase 2 Study Results
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics to Participate in Upcoming February Investor Conferences,2017-02-07 22:00:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-participate-upcoming-february-220000602.html,"[Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announc"
SAGE,SAGE:US,BBG0025X16Y5,"Hershey Trust Co Buys JD.com Inc, Barracuda Networks Inc, Global Blood Therapeutics Inc",2017-01-25 11:30:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Zn7goAY33LE/hershey-trust-co-buys-jdcom-inc-barracuda-networks-inc-global-blood-therapeutics-inc-cm737760,Hershey Trust Co New Purchases JD GBT GKOS MYOK VYGR XLRN Added Positions CUDA TEAM Reduced Positions HUBS New Purchases JD GBT GKOS MYOK VYGR XLRN New Purchases JD GBT GKOS MYOK VYGR XLRN
SAGE,SAGE:US,BBG0025X16Y5,"Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017",2017-01-03 21:10:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-present-j-p-211000058.html,"[Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the company is scheduled to present at the J.P."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics to Participate in Goldman Sachs Healthcare Conference,2016-12-29 21:10:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-participate-goldman-sachs-211000252.html,"[Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will participate in a fireside chat at the Goldman Sachs Healthcare CEOs Unscripted conference on Thursday, January 5th, 2017 at 2:30 p.m."
SAGE,SAGE:US,BBG0025X16Y5,First Week of August 2017 Options Trading For Sage Therapeutics (SAGE),2016-12-21 16:58:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UhJTgrv3z-k/first-week-of-august-2017-options-trading-for-sage-therapeutics-sage-cm724579,Investors in Sage Therapeutics Inc Symbol SAGE saw new options become available this week for the August 2017 expiration One of the key data points that goes into the price an option buyer is willing to pay is the time value so with 240 days until expiration the newly available
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces Initiation of Phase 2 Clinical Development for SAGE-217 in Mood Disorders,2016-12-19 12:11:06 +0000,http://www.publicnow.com/view/42612C6FF8E4176368BD6EEC145109F73A700880,[at noodls] - First patient dosed in Phase 2 proof-of-concept trial of SAGE-217 in major depressive disorder and trial sites open for Phase 2 trial of SAGE-217 in postpartum depression Four Phase 2 clinical programs ...
SAGE,SAGE:US,BBG0025X16Y5,Sage's Postpartum Depression Drug Likely To Catalyze Stock,2016-12-14 21:14:18 +0000,http://www.investors.com/news/technology/sage-therapeutics-baby-blues-drug-likely-to-catalyze-stock-in-2017/,Sage's Postpartum Depression Drug Likely To Catalyze Stock
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces Initiation of Phase 2 Clinical Development for SAGE-217 in Movement Disorders,2016-12-13 12:00:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-announces-initiation-phase-120000763.html,"[Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced the initiation of Phase 2 clinical development of SAGE-217, a novel, internally-developed, next generation oral GABAA receptor modulator that Sage is developing in both mood and movement disorders."
SAGE,SAGE:US,BBG0025X16Y5,"SAGE Therapeutics Inc (SAGE): What Just Happened, And What’s Next?",2016-12-07 18:41:22 +0000,http://www.insidermonkey.com/blog/sage-therapeutics-inc-sage-what-just-happened-and-whats-next-500780/,"SAGE Therapeutics Inc (SAGE): What Just Happened, And What’s Next?"
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Stock Up on SAGE-547 Regulatory Update,2016-12-07 15:59:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HYCkvv7ilvA/sage-therapeutics-stock-up-on-sage-547-regulatory-update-cm717938,Shares of Sage Therapeutics Inc SAGE gained 7 5 after the company announced its expedited development plan for SAGE 547 following the receipt of formal meeting minutes from a breakthrough therapy meeting with the FDA A look at the company s year to day share price movement shows that
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Stock Up on SAGE-547 Regulatory Update,2016-12-07 14:07:02 +0000,http://finance.yahoo.com/news/sage-therapeutics-stock-sage-547-140702127.html,Sage Therapeutics Stock Up on SAGE-547 Regulatory Update
SAGE,SAGE:US,BBG0025X16Y5,"Sage Therapeutics to Webcast R&D Day on December 13, 2016",2016-12-07 12:00:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-webcast-r-d-120000490.html,"[Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that it will webcast its R&D Day on Tuesday, December 13, 2016 from 12:30 p.m."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics CEO on postpartum depression drug,2016-12-06 18:53:00 +0000,http://finance.yahoo.com/video/sage-therapeutics-ceo-postpartum-depression-185300096.html,Sage Therapeutics CEO on postpartum depression drug
SAGE,SAGE:US,BBG0025X16Y5,Sage jumps 8% on expedited development plan for postpartum depression treatment,2016-12-06 13:20:51 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=61B5025F-3181-4AF3-909A-96924AFB1A47&siteid=yhoof2,Sage jumps 8% on expedited development plan for postpartum depression treatment
SAGE,SAGE:US,BBG0025X16Y5,Sage Announces Expedited Development Plan for SAGE-547 in the Treatment of Postpartum Depression based on FDA Breakthrough Therapy Meeting,2016-12-06 12:00:00 +0000,http://finance.yahoo.com/news/sage-announces-expedited-development-plan-120000253.html,"[Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced its expedited development plan for SAGE-547 following receipt of formal meeting minutes from a breakthrough therapy meeting with the U.S."
SAGE,SAGE:US,BBG0025X16Y5,SAGE Therapeutics (SAGE) Is Rising On Expedited Development Plan For SAGE-547,2016-12-06 09:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p4gCdDr45WQ/sage-therapeutics-sage-is-rising-on-expedited-development-plan-for-sage547-20161206-00649,SAGE Therapeutics (SAGE) Is Rising On Expedited Development Plan For SAGE-547
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics to Present at American Epilepsy Society 70th Annual Meeting,2016-12-01 21:30:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-present-american-epilepsy-213000729.html,"[Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced upcoming presentations at the American Epilepsy Society 70th Annual Meeting, taking place December 2-6, 2016 in Houston, TX."
SAGE,SAGE:US,BBG0025X16Y5,"SAGE Therapeutics, Inc. :SAGE-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016",2016-11-28 19:10:21 +0000,http://www.capitalcube.com/blog/index.php/sage-therapeutics-inc-sage-us-earnings-analysis-q3-2016-by-the-numbers-november-28-2016/,"SAGE Therapeutics, Inc. :SAGE-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016"
SAGE,SAGE:US,BBG0025X16Y5,What Trump isn't saying about drugmakers matters to investors,2016-11-22 13:00:00 +0000,http://www.cnbc.com/id/104121381?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104121381,What Trump isn't saying about drugmakers matters to investors
SAGE,SAGE:US,BBG0025X16Y5,"Notable Thursday Option Activity: FSLR, NTAP, SAGE",2016-11-17 17:51:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p2nXqWhHwN8/notable-thursday-option-activity-fslr-ntap-sage-cm710693,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in First Solar Inc Symbol FSLR where a total volume of 51 952 contracts has been traded thus far today a contract volume which is representative of approximately 5 2
SAGE,SAGE:US,BBG0025X16Y5,SAGE-547 Granted PRIME Designation by EMA for the Treatment of Postpartum Depression,2016-11-16 14:40:00 +0000,http://finance.yahoo.com/news/sage-547-granted-prime-designation-144000076.html,"[Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the European Medicines Agency has granted its PRIority MEdicines designation to SAGE-547 for the treatment of postpartum depression ."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics to Present at Society for Neuroscience 2016 Annual Meeting,2016-11-10 21:05:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-present-society-neuroscience-210500692.html,"[Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced upcoming presentations at the Society for Neuroscience 2016 Annual Meeting, taking place November 12-16, 2016 in San Diego, CA."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics to Present at the Stifel 2016 Healthcare Conference,2016-11-09 21:05:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-present-stifel-2016-210500302.html,"[Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will present at the Stifel 2016 Healthcare Conference at 11:00 AM ET on Wednesday, November 16, 2016 in New York, NY."
SAGE,SAGE:US,BBG0025X16Y5,Sage 3Q Loss of $1.15/Share Misses Street (SAGE),2016-11-05 13:40:00 +0000,http://www.investopedia.com/news/sage-therapeutics-3q-loss-115-share-sage/?partner=YahooSA,Sage 3Q Loss of $1.15/Share Misses Street (SAGE)
SAGE,SAGE:US,BBG0025X16Y5,Friday Wasn't Bad; Amazon-Induced Woes: Best of Kass,2016-11-05 01:00:00 +0000,https://www.thestreet.com/story/13882286/1/friday-wasn-t-bad-amazon-induced-woes-best-of-kass.html?puc=yahoo&cm_ven=YAHOO,Friday Wasn't Bad; Amazon-Induced Woes: Best of Kass
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Becomes Oversold (SAGE),2016-11-03 22:07:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/X5-5FIEPZBA/sage-therapeutics-becomes-oversold-sage-cm703673,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
SAGE,SAGE:US,BBG0025X16Y5,"SAGE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E",2016-11-03 20:38:08 +0000,http://biz.yahoo.com/e/161103/sage8-k.html,"SAGE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E"
SAGE,SAGE:US,BBG0025X16Y5,CORRECTING and REPLACING Sage Therapeutics Announces Third Quarter 2016 Financial Results and Provides SRSE European Update,2016-11-03 13:28:12 +0000,http://www.publicnow.com/view/F36E379CAF533F8E4C9F325DC171640D0CFCDE68,"[at noodls] - Positive Scientific Advice From European Medicines Agency on Development of SAGE-547 in SRSE Provides Regulatory Path in E.U. ... This is an abstract of the original noodl. To continue reading this document, ..."
SAGE,SAGE:US,BBG0025X16Y5,"SAGE THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report",2016-11-03 12:34:13 +0000,http://biz.yahoo.com/e/161103/sage10-q.html,"SAGE THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report"
SAGE,SAGE:US,BBG0025X16Y5,Q3 2016 SAGE Therapeutics Inc Earnings Release - Before Market Open,2016-11-03 11:07:07 +0000,http://biz.yahoo.com/research/earncal/20161103.html?t=sage,Q3 2016 SAGE Therapeutics Inc Earnings Release - Before Market Open
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics reports 3Q loss,2016-11-03 10:38:48 +0000,http://sg.finance.yahoo.com/news/sage-therapeutics-reports-3q-loss-103848513.html,Sage Therapeutics reports 3Q loss
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces Third Quarter 2016 Financial Results and Provides SRSE European Update,2016-11-03 10:37:15 +0000,http://www.publicnow.com/view/4435F59D1BC4D383FF669724A3C58DD90187CDA5,"[at noodls] - Positive Scientific Advice From European Medicines Agency on Development of SAGE-547 in SRSE Provides Regulatory Path in E.U. ... This is an abstract of the original noodl. To continue reading this document, ..."
SAGE,SAGE:US,BBG0025X16Y5,"Sage Therapeutics to Report Third Quarter 2016 Financial Results on Thursday, November 3, 2016",2016-10-27 21:48:03 +0000,http://www.publicnow.com/view/9826D5DB61D8D3EA6EB19B8E73A479EB3CD9C402,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, ..."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics and Collaborators Publish New Pre-clinical Data in Neuropharmacology Demonstrating a Novel Metabotropic Mechanism of Sage Compounds Resulting in Enhanced Effects,2016-10-20 11:18:07 +0000,http://www.publicnow.com/view/8DDD36E5D1756B2696031457FFA185303B5C2EBA,"[at noodls] - In vitro data show short exposure to certain neuroactive steroids, including allopregnanolone and novel Sage tool compound SGE-516, can have sustained effects through enhancement of extrasynaptic GABA ..."
SAGE,SAGE:US,BBG0025X16Y5,Analysts Predict 39% Upside For XBI,2016-10-13 14:40:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mmGvpHqZwfk/analysts-predict-39-upside-for-xbi-cm692798,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
SAGE,SAGE:US,BBG0025X16Y5,"BioMarin, Incyte, Kite Get Thumbs Up On Goldman Sachs Upgrade",2016-10-07 20:21:23 +0000,http://www.investors.com/news/technology/biomarin-incyte-kite-get-thumbs-up-on-goldman-sachs-upgrade/,"BioMarin, Incyte, Kite Get Thumbs Up On Goldman Sachs Upgrade"
SAGE,SAGE:US,BBG0025X16Y5,Sage Reports Additional Positive Data on Secondary Endpoints from Phase 2 Clinical Trial of SAGE-547 in Severe Postpartum Depression at the Marcé Society for Perinatal Mental Health Biennial Scientific Meeting,2016-09-27 11:00:00 +0000,http://finance.yahoo.com/news/sage-reports-additional-positive-data-110000858.html,"[Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced positive results on secondary endpoints from its Phase 2 clinical trial of SAGE-547 for the treatment of severe postpartum depression at The Marcé Society for Perinatal Mental Health held September 26 – 28, 2016 in Melbourne, Australia."
SAGE,SAGE:US,BBG0025X16Y5,"Commit To Buy Sage Therapeutics At $35, Earn 16.9% Annualized Using Options",2016-09-26 16:27:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qH1pKPLWPQU/commit-to-buy-sage-therapeutics-at-35-earn-169-annualized-using-options-cm684663,Investors eyeing a purchase of Sage Therapeutics Inc Symbol SAGE shares but cautious about paying the going market price of 46 60 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the May
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics to Present at the Leerink Partners Rare Disease Roundtable,2016-09-21 20:21:01 +0000,http://www.publicnow.com/view/CB510F4542A8F7B9E225BFB964629B7F465723E0,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, ..."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics to Present at the Neurocritical Care Society 14th Annual Meeting,2016-09-16 11:00:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-present-neurocritical-care-110000587.html,"[Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced upcoming poster presentations at the Neurocritical Care Society 14th Annual Meeting, taking place from September 15-18 in National Harbor, Md."
SAGE,SAGE:US,BBG0025X16Y5,"SAGE THERAPEUTICS, INC. Files SEC form 8-K, Other Events",2016-09-15 20:07:11 +0000,http://biz.yahoo.com/e/160915/sage8-k.html,"SAGE THERAPEUTICS, INC. Files SEC form 8-K, Other Events"
SAGE,SAGE:US,BBG0025X16Y5,"SAGE Therapeutics, Inc. :SAGE-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016",2016-09-13 19:16:24 +0000,http://www.capitalcube.com/blog/index.php/sage-therapeutics-inc-sage-us-earnings-analysis-q2-2016-by-the-numbers-september-13-2016/,"SAGE Therapeutics, Inc. :SAGE-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016"
SAGE,SAGE:US,BBG0025X16Y5,"SAGE THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial State",2016-09-09 20:32:08 +0000,http://biz.yahoo.com/e/160909/sage8-k.html,"SAGE THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial State"
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces Pricing of Public Offering of Common Stock,2016-09-09 00:59:04 +0000,http://www.publicnow.com/view/6FD8E4A957690C1AB9B18E9850BB5D53FB301FD7,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, ..."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces Proposed Public Offering of Common Stock,2016-09-07 20:09:03 +0000,http://www.publicnow.com/view/0BB18FBA3FC0BCA7A4FA2FD347590B1B7D667802,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, ..."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics: Breakthrough Status for Depression Drug,2016-09-07 17:18:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zvTGkWfNZwM/sage-therapeutics-breakthrough-status-for-depression-drug-cm675738,Sage Therapeutics Inc SAGE announced that the FDA has granted Breakthrough Therapy designation to its experimental drug SAGE 547 which is being developed for the treatment of postpartum depression PPD in women Shares gained more than 12 in yesterday s trading session
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics: Breakthrough Status for Depression Drug,2016-09-07 14:50:02 +0000,http://finance.yahoo.com/news/sage-therapeutics-breakthrough-status-depression-145002861.html,Sage Therapeutics: Breakthrough Status for Depression Drug
SAGE,SAGE:US,BBG0025X16Y5,"Tuesday Sector Leaders: Precious Metals, Drugs",2016-09-06 20:17:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/07-op_tPYPE/tuesday-sector-leaders-precious-metals-drugs-cm675192,In trading on Tuesday precious metals shares were relative leaders up on the day by about 5 Leading the group were shares of Tanzanian Royalty Exploration Company TRX up about 14 1 and shares of Almaden Minerals AAU up about 12 9 on the day Also showing relative strength
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics stock rises 12% after FDA designates drug a 'breakthrough therapy',2016-09-06 16:49:06 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=B1E5E9B9-A85A-4BC9-A55E-82F76839DE7C&siteid=yhoof2,Sage Therapeutics stock rises 12% after FDA designates drug a 'breakthrough therapy'
SAGE,SAGE:US,BBG0025X16Y5,Sage Receives FDA Breakthrough Therapy Designation for SAGE-547 for the Treatment of Postpartum Depression,2016-09-06 13:19:11 +0000,http://www.publicnow.com/view/BE7EDB46E823CB4BBE728108112B4EA623F88468,"[at noodls] - Designation offers potential for expedited development and review, and underscores significant unmet need in women with postpartum depression CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: ..."
SAGE,SAGE:US,BBG0025X16Y5,Cepheid Jumps On $4 Billion Acquisition By Danaher,2016-09-06 13:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/47bA0PxniQ8/cepheid-jumps-on-4-billion-acquisition-by-danaher-20160906-01023,Cepheid Jumps On $4 Billion Acquisition By Danaher
SAGE,SAGE:US,BBG0025X16Y5,"Sage Therapeutics' Drug Gets ""breakthrough Therapy"" Designation, Shares Jump 12%",2016-09-06 13:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZtVdH4gvzh8/sage-therapeutics-drug-gets-breakthrough-therapy-designation-shares-jump-12-20160906-01022,"Sage Therapeutics' Drug Gets ""breakthrough Therapy"" Designation, Shares Jump 12%"
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics and Collaborators Announce Publication Highlighting Epidemiology and Burden of Illness for Super-Refractory Status Epilepticus in Journal of Medical Economics,2016-08-30 11:23:09 +0000,http://www.publicnow.com/view/FC7DE0336CFA1ADABAC4A2D948196173D4029665,"[at noodls] - Largest epidemiology-focused SRSE study to date and first study to examine economic impact of related hospitalization Study suggests SRSE is associated with high mortality and morbidity, and significant ..."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics and Collaborators Announce Publication Highlighting Epidemiology and Burden of Illness for Super-Refractory Status Epilepticus in Journal of Medical Economics,2016-08-30 11:00:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-collaborators-announce-publication-110000955.html,"[Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced the publication of a study conducted with collaborators from Massachusetts General Hospital on the epidemiology of super-refractory status epilepticus ."
SAGE,SAGE:US,BBG0025X16Y5,We Did The Math XBI Can Go To $83,2016-08-18 14:46:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-JGevNH8D4A/we-did-the-math-xbi-can-go-to-83-cm667025,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"
SAGE,SAGE:US,BBG0025X16Y5,SAGE Therapeutics (SAGE) Stock Closes Sharply Lower on 2Q Loss,2016-08-09 21:50:00 +0000,https://www.thestreet.com/story/13670504/1/sage-therapeutics-sage-stock-closes-sharply-lower-on-2q-loss.html?puc=yahoo&cm_ven=YAHOO,SAGE Therapeutics (SAGE) Stock Closes Sharply Lower on 2Q Loss
SAGE,SAGE:US,BBG0025X16Y5,Edited Transcript of SAGE earnings conference call or presentation 9-Aug-16 12:00pm GMT,2016-08-09 15:28:47 +0000,http://finance.yahoo.com/news/edited-transcript-sage-earnings-conference-152847676.html,Edited Transcript of SAGE earnings conference call or presentation 9-Aug-16 12:00pm GMT
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update,2016-08-09 11:00:12 +0000,http://www.publicnow.com/view/64A85C5801B5F2D68F89653BC34BA5E7355AE76E,[at noodls] - Portfolio Expansion Underway Based on Recent Positive Data from SAGE-547 and SAGE-217 Top-line Data Readout of Phase 3 STATUS Trial in SRSE Now Expected in 1H 2017 Dosing Commenced in Expanded Phase 2 ...
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics reports 2Q loss,2016-08-09 10:47:48 +0000,http://sg.finance.yahoo.com/news/sage-therapeutics-reports-2q-loss-104748782.html,Sage Therapeutics reports 2Q loss
SAGE,SAGE:US,BBG0025X16Y5,"SAGE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E",2016-08-09 10:35:59 +0000,http://biz.yahoo.com/e/160809/sage8-k.html,"SAGE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E"
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics to Present at the Canaccord Genuity 36th Annual Growth Conference,2016-08-03 22:10:00 +0000,http://finance.yahoo.com/news/sage-therapeutics-present-canaccord-genuity-221000286.html,"[Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will present at the Canaccord Genuity 36th Annual Growth Conference at 1:00 PM ET on August 10, in Boston, MA."
SAGE,SAGE:US,BBG0025X16Y5,"Sage Therapeutics to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016",2016-08-02 21:22:05 +0000,http://www.publicnow.com/view/1FD1F306446C199DB765F531D1281CD7A2AA3EA6,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, ..."
SAGE,SAGE:US,BBG0025X16Y5,How To Get A 1-On-1 With An Expert On SAGE-547,2016-07-28 21:24:15 +0000,http://finance.yahoo.com/news/1-1-expert-sage-547-212415842.html,How To Get A 1-On-1 With An Expert On SAGE-547
SAGE,SAGE:US,BBG0025X16Y5,Edited Transcript of SAGE earnings conference call or presentation 5-May-16 8:30pm GMT,2016-07-22 19:18:40 +0000,http://finance.yahoo.com/news/edited-transcript-sage-earnings-conference-191840343.html,Edited Transcript of SAGE earnings conference call or presentation 5-May-16 8:30pm GMT
SAGE,SAGE:US,BBG0025X16Y5,"SAGE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statem",2016-07-21 20:11:28 +0000,http://biz.yahoo.com/e/160721/sage8-k.html,"SAGE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statem"
SAGE,SAGE:US,BBG0025X16Y5,Sage Appoints Geno Germano to Company's Board of Directors,2016-07-19 11:00:00 +0000,http://finance.yahoo.com/news/sage-appoints-geno-germano-companys-110000773.html,"[Business Wire] - Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, announced today that Geno Germano has been appointed to Sage’s Board of Directors."
SAGE,SAGE:US,BBG0025X16Y5,What Investors Might Have Missed in the Market This Week,2016-07-16 01:09:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pKiWmPN-W0k/what-investors-might-have-missed-in-the-market-this-week-cm650109,"Stocks in the U.S. markets gave up some of the week's gains on Friday, after moving higher for four sessions that sent the major indexes to record highs. The recent jobs report and a healthy gain in"
SAGE,SAGE:US,BBG0025X16Y5,"SAGE THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-07-13 20:58:23 +0000,http://biz.yahoo.com/e/160713/sage8-k.html,"SAGE THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
SAGE,SAGE:US,BBG0025X16Y5,"Coverage of Top Gainers SAGE Therapeutics, Seagate Technology, and Cascadian Therapeutics",2016-07-13 13:26:56 +0000,http://news.investornetwork.com/2016/07/13/coverage-of-top-gainers-sage-therapeutics-seagate-technology-and-cascadian-therapeutics/?1=1&1468416416,"Coverage of Top Gainers SAGE Therapeutics, Seagate Technology, and Cascadian Therapeutics"
SAGE,SAGE:US,BBG0025X16Y5,Trending Stocks This Week,2016-07-13 11:56:57 +0000,http://news.investornetwork.com/2016/07/13/trending-stocks-this-week/?1=1&1468411017,Trending Stocks This Week
SAGE,SAGE:US,BBG0025X16Y5,[$$] Sage Shares Jump on Postpartum Depression Drug Trial Results,2016-07-13 11:26:06 +0000,http://www.wsj.com/articles/sage-shares-jump-on-postpartum-depression-drug-trial-results-1468332093?ru=yahoo?mod=yahoo_itp,[$$] Sage Shares Jump on Postpartum Depression Drug Trial Results
SAGE,SAGE:US,BBG0025X16Y5,What Happened in the Stock Market Today,2016-07-12 23:50:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mZjl4K4ac0E/what-happened-in-the-stock-market-today-cm648296,"Stocks pushed further into record territory on Tuesday by posting solid gains. The Dow Jones Industrial Average (DJINDICES   DJI) rose by 121 points, or 0.7% to reach a new high one day after the broader"
SAGE,SAGE:US,BBG0025X16Y5,"SAGE On A High, JUNO Rockets As FDA Lifts Clinical Hold, FDA Panel Nod For AMGN",2016-07-12 23:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ji0yZbPjQVA/sage-on-a-high-juno-rockets-as-fda-lifts-clinical-hold-fda-panel-nod-for-amgn-20160712-01341,"SAGE On A High, JUNO Rockets As FDA Lifts Clinical Hold, FDA Panel Nod For AMGN"
SAGE,SAGE:US,BBG0025X16Y5,"After-hours buzz: JUNO, TEVA, SAGE & more",2016-07-12 22:14:41 +0000,http://www.cnbc.com/id/103783426?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103783426,"After-hours buzz: JUNO, TEVA, SAGE & more"
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics shares soar on positive postpartum depression drug results,2016-07-12 21:19:19 +0000,http://www.cnbc.com/id/103781733?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103781733,Sage Therapeutics shares soar on positive postpartum depression drug results
SAGE,SAGE:US,BBG0025X16Y5,Close Update: U.S. Stocks Touch New Record Highs as Risk-On Sentiment Emerges,2016-07-12 21:05:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NnOL8m4fKOI/close-update-us-stocks-touch-new-record-highs-as-risk-on-sentiment-emerges-cm648243,"The S&P 500 and the Dow Jones Industrial Average closed at new record highs in the U.S. on Tuesday, while the Nasdaq Composite was at this year's peak as investors jumped back into equities amid rising oil prices and"
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Inc: SAGE Stock Jumps 40% on Phase-2 PPD Results,2016-07-12 20:49:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HSDAGFBFHqs/sage-therapeutics-inc-sage-stock-jumps-40-on-phase-2-ppd-results-cm648214,"Less than a couple weeks ago, yours truly penned a list of biotech names with catalysts on the calendar for the third quarter  that could"
SAGE,SAGE:US,BBG0025X16Y5,Here's Why Sage Therapeutics (SAGE) Stock is Soaring 40% Today,2016-07-12 20:48:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/27uMKHsL1Wg/heres-why-sage-therapeutics-sage-stock-is-soaring-40-today-cm648211,"On Tuesday, shares of biopharmaceutical company Sage Therapeutics Inc. SAGE are sparing, up around 40% in afternoon trading after the company's treatment for severe postpartum depression showed positive results in a phase 2 study. Postpartum depression is a mood"
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics (SAGE) CEO Jonas Tells CNBC He's 'Very Excited' By Positive Drug Results,2016-07-12 20:31:00 +0000,https://www.thestreet.com/story/13637352/1/sage-therapeutics-sage-ceo-jonas-tells-cnbc-he-s-very-excited-by-positive-drug-results.html?puc=yahoo&cm_ven=YAHOO,Sage Therapeutics (SAGE) CEO Jonas Tells CNBC He's 'Very Excited' By Positive Drug Results
SAGE,SAGE:US,BBG0025X16Y5,"Seagate, Alcoa and United climb; Fastenal slides",2016-07-12 20:15:57 +0000,http://sg.finance.yahoo.com/news/seagate-alcoa-united-climb-fastenal-201557639.html,"Seagate, Alcoa and United climb; Fastenal slides"
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics' Post-Partum Depression Drug Scores; Stock Up,2016-07-12 20:07:40 +0000,http://www.investors.com/news/technology/sage-therapeutics-post-partum-depression-drug-scores-stock-up/?ven=YahooCP&src=AURLLED&ven=yahoo,Sage Therapeutics' Post-Partum Depression Drug Scores; Stock Up
SAGE,SAGE:US,BBG0025X16Y5,Here's Why Sage Therapeutics (SAGE) Stock is Soaring 40% Today,2016-07-12 18:11:06 +0000,http://finance.yahoo.com/news/heres-why-sage-therapeutics-sage-181106474.html,Here's Why Sage Therapeutics (SAGE) Stock is Soaring 40% Today
SAGE,SAGE:US,BBG0025X16Y5,One hot biotech,2016-07-12 18:06:00 +0000,http://finance.yahoo.com/video/one-hot-biotech-180600220.html,One hot biotech
SAGE,SAGE:US,BBG0025X16Y5,Here's Why SAGE Therapeutics Inc. Is Surging Today,2016-07-12 17:50:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pDnZshRjsvg/heres-why-sage-therapeutics-inc-is-surging-today-cm648109,Image source  Getty Images.  What   It's a great day to be an investor in SAGE Therapeutics (NASDAQ  SAGE) . Shares of the clinical stage biotech are up more than 37% as
SAGE,SAGE:US,BBG0025X16Y5,Midday Update: Stocks Set New Records on Tuesday,2016-07-12 17:05:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8TZscVTzd7w/midday-update-stocks-set-new-records-on-tuesday-cm648095,"Tuesday was another record setting day on Wall Street as improved investor confidence in the U.S. economy coupled with upbeat corporate earnings drove the Dow and S&P 500 to all time highs and the Nasdaq above 5,000 for the"
SAGE,SAGE:US,BBG0025X16Y5,Here's Why SAGE Therapeutics Inc. Is Surging Today,2016-07-12 16:31:00 +0000,http://www.fool.com/investing/2016/07/12/heres-why-sage-therapeutics-inc-is-surging-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Here's Why SAGE Therapeutics Inc. Is Surging Today
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics surges on postpartum depression drug study,2016-07-12 14:49:57 +0000,http://sg.finance.yahoo.com/news/sage-therapeutics-surges-postpartum-depression-144957904.html,Sage Therapeutics surges on postpartum depression drug study
SAGE,SAGE:US,BBG0025X16Y5,"Pre-Market Most Active for Jul 12, 2016 :  SAGE, MT, BAC, FCX, AA, CNHI, CHK, STX, SHPG, XIV, QQQ, TLT",2016-07-12 13:04:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/heSWfi0UL6M/pre-market-most-active-for-jul-12-2016-sage-mt-bac-fcx-aa-cnhi-chk-stx-shpg-xiv-qqq-tlt-cm647672,"The NASDAQ 100 Pre Market Indicator is up 17.53 to 4,572.24. The total Pre Market volume is currently 8,844,780 shares traded. The following are the most active stocks for the pre market session Sage Therapeutics, Inc. ( SAGE )"
SAGE,SAGE:US,BBG0025X16Y5,Sage Shares Jump on Postpartum Depression Drug Trial Results,2016-07-12 10:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nyE7PZUIeHE/sage-shares-jump-on-postpartum-depression-drug-trial-results-20160712-00775,Sage Shares Jump on Postpartum Depression Drug Trial Results
SAGE,SAGE:US,BBG0025X16Y5,Sage Reports Positive Top-line Results Including Demonstration of 30-Day Durability from Phase 2 Clinical Trial of SAGE-547 in Severe Postpartum Depression,2016-07-12 10:43:07 +0000,http://www.publicnow.com/view/58C865FBC140DB28EF51783B616F6890069BA732,[at noodls] - Primary endpoint achieved with statistical significance at 60 hours maintained through 30 days 70% remission achieved at 60 hours of SAGE-547 treatment and maintained at 30-day follow-up Company expects ...
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Inc. (SAGE) Is Surging On Phase 2 Results For SAGE-547,2016-07-12 09:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WY1x9wAC368/sage-therapeutics-inc-sage-is-surging-on-phase-2-results-for-sage547-20160712-00669,Sage Therapeutics Inc. (SAGE) Is Surging On Phase 2 Results For SAGE-547
SAGE,SAGE:US,BBG0025X16Y5,MARKET SNAPSHOT: Wall Street On Track For Another Record-setting Session,2016-07-12 09:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9VdGYvFYMH4/market-snapshot-wall-street-on-track-for-another-recordsetting-session-20160712-00630,MARKET SNAPSHOT: Wall Street On Track For Another Record-setting Session
SAGE,SAGE:US,BBG0025X16Y5,"Notable Wednesday Option Activity: OUTR, NUE, SAGE",2016-07-06 21:36:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dY3Tg9kjy1U/notable-wednesday-option-activity-outr-nue-sage-cm645490,"Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Outerwall Inc (Symbol OUTR), where a total of 1,441 contracts have traded so far, representing approximately 144,100 underlying shares. That amounts to"
SAGE,SAGE:US,BBG0025X16Y5,10 Biotech Stocks That Could Erupt Within Months,2016-07-01 23:49:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g5fUuO3fMgs/10-biotech-stocks-that-could-erupt-within-months-cm644110,"It's time to flip the calendar to a new month, but a new quarter as well, resetting the psychological clock for investors. We're also entering a time of year that's"
SAGE,SAGE:US,BBG0025X16Y5,"Thursday's ETF Movers: GDXJ, XBI",2016-06-09 20:11:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8FchP714Luo/thursdays-etf-movers-gdxj-xbi-cm633140,"In trading on Thursday, the Junior Gold Miners ETF ( GDXJ ) is outperforming other ETFs, up about 1.9% on the day. Components of that ETF showing particular strength include shares of Fortuna Silver Mines ( FSM ), up"
SAGE,SAGE:US,BBG0025X16Y5,Sage Reports Positive Top-line Results from Phase 1 Clinical Program of SAGE-217,2016-06-07 20:28:03 +0000,http://www.publicnow.com/view/791C3358ABF1BCCE395A4ADE8EBC5CF1F82C031B,[at noodls] - SAGE-217 was well-tolerated in single and multiple ascending doses Results consistent with predicted pharmacokinetic and pharmacologic profile Initiation of Phase 2 clinical trials planned for second half ...
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics to Present at the Goldman Sachs 37th Annual Global Healthcare Conference,2016-06-01 20:45:02 +0000,http://www.publicnow.com/view/111D420F10AFA8D17E56A78DDD804DE75C08267E,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, ..."
SAGE,SAGE:US,BBG0025X16Y5,"Health Care Sector Update for 05/27/2016: GSK, RLYP, SAGE, AZN",2016-05-27 20:20:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KK4fyiVGpR8/health-care-sector-update-for-05272016-gsk-rlyp-sage-azn-cm627734,"Top Health Care Stocks JNJ +0.01% PFE +0.32% MRK +0.90% ABT +0.05% AMGN +0.68% Health care stocks were hanging on to small gains this afternoon, with the NYSE Health Care Index rising about 0.2% while shares of health care"
SAGE,SAGE:US,BBG0025X16Y5,"Health Care Sector Update for 05/27/2016: TTNP,RLYP,SAGE",2016-05-27 18:04:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PVaVdjyDVZ0/health-care-sector-update-for-05272016-ttnprlypsage-cm627650,"Top Health Care Stocks JNJ +0.11% PFE +0.55% MRK +1.08% ABT +0.09% AMGN +0.55% Health care stocks were increasing this afternoon, with the NYSE Health Care Index rising about 0.4% while shares of health care companies in the S&P"
SAGE,SAGE:US,BBG0025X16Y5,"TTNP On A High, Double Blessing For NERV, AVIR In Trouble, SAGE Awaits Data",2016-05-26 23:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OGx5Yl3_GpE/ttnp-on-a-high-double-blessing-for-nerv-avir-in-trouble-sage-awaits-data-20160526-01241,"TTNP On A High, Double Blessing For NERV, AVIR In Trouble, SAGE Awaits Data"
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces Completion of Enrollment for Phase 2 Proof-of-Concept Trial of SAGE-547 in Severe Postpartum Depression,2016-05-26 20:17:03 +0000,http://www.publicnow.com/view/EA5DD557A23761AA3149FDFB591C2821655CFDAA,"[at noodls] - Full top-line dataset, including 30-day follow-up, expected in July 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing ..."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics reports 1Q loss,2016-05-05 21:11:33 +0000,http://sg.finance.yahoo.com/news/sage-therapeutics-reports-1q-loss-211133789.html,Sage Therapeutics reports 1Q loss
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces First Quarter 2016 Financial Results,2016-05-05 20:44:17 +0000,http://www.publicnow.com/view/10E34C8FB29B226AAE62B416623DF85BEE8D5FE6,"[at noodls] - Five data presentations across two indications presented at AAN Annual Meeting Multiple upcoming milestones and events planned for 2016 Conference call today at 4:30 PM ET CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ..."
SAGE,SAGE:US,BBG0025X16Y5,"Sage Therapeutics to Report First Quarter 2016 Financial Results on Thursday, May 5, 2016",2016-04-28 20:15:36 +0000,http://www.publicnow.com/view/76BA9C072B2227DB42E69763DB628654AAF30BCD,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, ..."
SAGE,SAGE:US,BBG0025X16Y5,"Noteworthy Monday Option Activity: LRN, SAGE, CHUY",2016-04-18 21:00:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0Aoo0bjcxac/noteworthy-monday-option-activity-lrn-sage-chuy-cm607848,"Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in K12 Inc (Symbol LRN), where a total volume of 3,674 contracts has been traded thus far today, a contract volume which"
SAGE,SAGE:US,BBG0025X16Y5,"Sage Therapeutics Expands Scientific, Clinical and Burden of Illness Data for SAGE-547 in SRSE and Essential Tremor at the 2016 American Academy of Neurology Annual Meeting",2016-04-17 20:46:25 +0000,http://www.publicnow.com/view/8FC63ADDE9CB222C8C731BB27BCE5EEF598485A6,[at noodls] - SAGE-547 response rate in SRSE Phase 1/2 trial not impacted by patient characteristics Potential pharmacodynamic biomarker identified for SAGE-547 informs STATUS Trial protocol Analyses from hospital chargemaster ...
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics to Present Data at the Society of Biological Psychiatry 71st Annual Scientific Meeting,2016-03-28 11:08:25 +0000,http://www.publicnow.com/view/F00F05390840EFC8CAA460C5CE653A16CFCB2EF9,[at noodls] - First time detailed data for SAGE-547 in postpartum depression (PPD) to be presented PPD data includes secondary endpoints and timeline of response SAGE-718 pre-clinical data unveiled in late-breaker First ...
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics reports 4Q loss,2016-02-24 13:01:33 +0000,http://sg.finance.yahoo.com/news/sage-therapeutics-reports-4q-loss-130133725.html,Sage Therapeutics reports 4Q loss
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces Pricing of Public Offering of Common Stock,2016-01-07 02:57:06 +0000,http://www.noodls.com/view/7DB3A5336839CA7CA9D415D115D85034DE7AD4C1,"[at noodls] - CAMBRIDGE, Mass., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Sage Therapeutics, Inc. (Nasdaq:SAGE), a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients ..."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics Announces Proposed Public Offering of Common Stock,2016-01-05 21:20:09 +0000,http://www.noodls.com/view/B55B1139D995FE590E02AE5B4B682836F417701D,"[at noodls] - , (GLOBE NEWSWIRE) -- (Nasdaq:SAGE), a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) ..."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference,2016-01-04 11:58:04 +0000,http://www.noodls.com/view/80AFA7AAC9C47DE5077C2227A030FE417849234F,"[at noodls] - CAMBRIDGE, Mass., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system ..."
SAGE,SAGE:US,BBG0025X16Y5,SAGE Updates Guidance for Top-Line Results of Phase 3 STATUS Trial of SAGE-547,2015-12-15 11:46:12 +0000,http://www.noodls.com/view/F405132156606E66BAF31A8CABCCBAA368B6DE8B,"[at noodls] - CAMBRIDGE, Mass., Dec. 15, 2015 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ:SAGE) today announced updated guidance for the expected readout of top-line results for its STATUS Trial (SAGE-547 Treatment ..."
SAGE,SAGE:US,BBG0025X16Y5,SAGE to Present Three Poster Presentations at the American Epilepsy Society 69th Annual Meeting,2015-12-02 13:17:36 +0000,http://www.noodls.com/view/9A8F3069C04E05B37E2E0036B8D216652DB3F9C5,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE) today announced upcoming medical/scientific poster presentations at the American Epilepsy Society 69th Annual Meeting, taking place ..."
SAGE,SAGE:US,BBG0025X16Y5,Sage Therapeutics reports 3Q loss,2015-11-06 00:09:32 +0000,http://sg.finance.yahoo.com/news/sage-therapeutics-reports-3q-loss-000932011.html,Sage Therapeutics reports 3Q loss
SAGE,SAGE:US,BBG0025X16Y5,SAGE Announces Third Quarter 2015 Financial Results and Recent Pipeline Progress,2015-11-05 21:32:25 +0000,http://www.noodls.com/view/18DA74D71460B3B542C2EAD0931883D751DA8002,[at noodls] - SAGE Announces Third Quarter 2015 Financial Results and Recent Pipeline Progress
SAGE,SAGE:US,BBG0025X16Y5,SAGE Announces Presentations at Upcoming November Investor Conferences,2015-11-03 23:07:09 +0000,http://www.noodls.com/view/C749AB2432E1FAE3A0053691A4E6DB417E8815D2,[at noodls] - SAGE Announces Presentations at Upcoming November Investor Conferences
SAGE,SAGE:US,BBG0025X16Y5,"SAGE to Report Third Quarter 2015 Financial Results on Thursday, November 5, 2015",2015-10-29 20:18:09 +0000,http://www.noodls.com/view/2732B6753BF6F0AA5231091A6D985F978EBB173E,"[at noodls] - SAGE to Report Third Quarter 2015 Financial Results on Thursday, November 5, 2015"
SAGE,SAGE:US,BBG0025X16Y5,SAGE to Present Data at Upcoming Scientific Conferences,2015-10-08 11:14:02 +0000,http://www.noodls.com/view/CC551D1DC53D0D6E8538D0A6ACC19FAA7E8CDFF1,"[at noodls] - CAMBRIDGE, Mass., Oct. 08, 2015 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ:SAGE) today announced upcoming data poster presentations at the 13th Annual Neurocritical Care Society Meeting, taking place ..."
SAGE,SAGE:US,BBG0025X16Y5,SAGE Announces Initiation of Phase 1 and First Dosing of SAGE-217,2015-10-06 10:54:05 +0000,http://www.noodls.com/view/DF0A81606B2E84C8742E5F46F13E350A02C6B374,"[at noodls] - CAMBRIDGE, Mass., Oct. 06, 2015 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ:SAGE) today announced it has initiated dosing in a Phase 1 single ascending dose trial evaluating SAGE-217 in healthy volunteers. ..."
